<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099747</url>
  </required_header>
  <id_info>
    <org_study_id>EBMT-RACE</org_study_id>
    <secondary_id>2014-000363-40</secondary_id>
    <nct_id>NCT02099747</nct_id>
  </id_info>
  <brief_title>hATG+CsA vs hATG+CsA+Eltrombopag for SAA</brief_title>
  <acronym>RACE</acronym>
  <official_title>A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Group for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The null hypothesis of no difference in CR% at 3 months between the arms will be tested
      against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds
      ratio for arm yielded by this model.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a superiority trial aiming to increase the 3 month complete response rate. The sample
      size is calculated on the hypothesis that the experimental treatment will increase the 3
      months response rate up to 21% (by 3 folds, based on the 7% reported in Scheinberg et al
      [17]). Under these assumptions, the sample size to reject the null hypothesis is n=96
      patients for each treatment arm, increased by 4% for possibly not evaluable patients (total
      number of 200 patients, 100 each treatment arm). Statistical design for sample size
      calculation: increase from 7% (control arm) to 21% (investigational arm) in 3 month complete
      response rate (two-sided binomial test); alpha-error 0.05; power 0.8.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate</measure>
    <time_frame>3 months</time_frame>
    <description>The primary objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated AA patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to best heamatological response</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heamatological Response at 6, 12, 18 and 24 months</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of response</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse rate</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidences of clonal evolution</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of PNH population occurrence and clinical hemolytic PNH occurrence</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of discontinuation of immunosuppressive therapy</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CsA-independent hematological response at 24 months</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for transfusions and number of transfusions required from treatment</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for any supportive care</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of number of SAEs between the two arms</measure>
    <time_frame>2 year</time_frame>
    <description>To look for the safety and tolerability of the investigational treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>hATG + CsA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hATG</intervention_name>
    <arm_group_label>hATG + CsA</arm_group_label>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
    <other_name>ATGAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <arm_group_label>hATG + CsA</arm_group_label>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of severe or very severe aplastic anemia, defined by [29]:

             At least two of the following:

             Absolute neutrophil counts &lt;0.5 x 109/L (severe) or &lt;0.2 x 109/L (very severe)
             Platelet counts &lt;20 x 109/L Reticulocyte counts &lt;60 x 109/L Hypocellular bone marrow
             (&lt;30% cellularity), without evidences of fibrosis or malignant cells

          2. Male or female age &gt; 14 years;

          3. Written informed consent

          4. Willing and able to comply with all of the requirements and visits in the protocol

          5. Understands that they can be randomised to either treatment arm

          6. Negative pregnancy test for women of child bearing age

        Exclusion Criteria:

          1. Prior immunosuppressive therapy with ATG (horse of rabbit) or any other lymphocyte
             depleting agent (i.e., alemtuzumab)

          2. Eligibility to a sibling allogeneic stem cell transplantation

          3. Evidence of a myelodysplastic syndrome, defined by the presence of myelodysplastic
             features, excess of blasts or karyotypic abnormalities typical of MDS (according to
             revised WHO 2008 criteria) [30],, as well as other primitive marrow disease. Patients
             with diagnosis of AA with cytogenetic abnormalities which are recurrent in MDS
             (according to revised WHO 2008 criteria) [30] should be included in this category, and
             are not eligible for the study; patients with del(20q), +8 and -Y are not included in
             this category, and thus are eligible for this study. The list of karyotypic
             abnormalities which qualifies for the diagnosis of MDS are listed in the Appendix.

          4. History or clinical suspect of constitutional aplastic anemia (i.e. Fanconi Anemia
             with positive DEB/MMC test or Dyskeratosis Congenita)

          5. History of malignant tumors with active disease within 5 years from enrollment, and/or
             previous chemo-radiotherapy

          6. Previous history of stem cell transplantation

          7. Treatment with cyclosporin A &lt;2 weeks before enrollment

          8. Treatment with G-CSF &lt;2 weeks before enrollment

          9. CMV viremia, as defined by positive PCR or pp65 test

         10. WHO performance status â‰¥3

         11. Pregnant or breast feeding patients

         12. Patients with hepatic, renal or cardiac failure, or any other life- threatening
             concurrent disease

         13. Patients with HIV infection

         14. Patients without social health care assistance

         15. Patients for whom there is no availability of horse-ATG (ATGAM)

         16. Participation in another clinical trial within 1 month before the start of this trial

         17. Patients and/or female partners of male patients not using highly effective method of
             birth control i.e. intrauterine device (IUD), hormonal (oral pill, injection,
             implants), tubal ligation or partner's vasectomy

         18. subjects with known hypersensitivity to any of the component medications

        The presence of a Paroxysmal Nocturnal Hemoglobinuria clone is not an exclusion criterion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Risitano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II Medical School, Haematology Division, Napels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regis Peffault de Latour, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis Hospital, Haematology Division, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain Barrois, MSc</last_name>
    <phone>+31 71526</phone>
    <phone_ext>5005</phone_ext>
    <email>alain.barrois@ebmt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marleen van Os, MSc</last_name>
    <phone>+31 71526</phone>
    <phone_ext>1988</phone_ext>
    <email>marleen.van_os_fransen@ebmt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Deconinck, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Haut-LÃ©vÃ¨que</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Tabrizi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiorenza Barraco, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regis Peffault de la Tour, Prof, MD</last_name>
    </contact>
    <investigator>
      <last_name>Regis Peffault de la Tour, Prof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Recher, Prof, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tim BrÃ¼mmendorf, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander RÃ¶th, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Schafhausen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnold Ganser, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Britta HÃ¶chsmann, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Schlenk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Rambaldi, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto G. Gaslini children's Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria-Theresa van Lint, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS ca Granda Ospedale</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wilma Barcelini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>`Federico II` Medical School</name>
      <address>
        <city>Napels</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Risitano</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Risitano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Sapienza University Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Foa, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sacha Zeerleder, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stijn Halkes, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Blanca Xicoy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Polo Zarzuela, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Rosell Mas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Donostia Hospital</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isidro Jarque Ramos, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominik Heim, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damian Finnegan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. James Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Hill, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Marsh, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aplastic Anaemia</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>HATG</keyword>
  <keyword>ATGAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

